Matthew Brams, MD: A Multidose ADHD Pill


CTx-1301's formulation enables 3 different doses within 1 pill for ADHD.

Researchers are touting a new treatment formulated in a new delivery system that shrinks the tablet, enabling researchers to put 3 doses of CTx-1301 into the size of 1 pill.

In data presented during the American Professional Society of ADHD and Related Disorders (APSARD) 2021 Annual Conference, researchers showed the drug can be effective treating attention deficit/hyperactivity disorder (ADHD) in both high and low doses.

In an interview with HCPLive®, Matthew Brams, MD, Chief Medical Officer of Cingulate Therapeutics, and Shane Schaffer, PharmD, CEO of Cingulate, said the unique formulation could be a boost for treating ADHD over the course of a day.

Bram said most drugs on the market for ADHD work effectively, but the majority have a 8-12 hour duration. CTx-1301 contains an immediate pulse, a pulse 3 hours later, and a 20% proportion that is saved for 7 hours later.

This boost given 7 hours following taking the actual treatment limits the amount of pills needed and prevents a crash.Bram said around 60% of ADHD patients require a booster dose, but with it built right into the tablet it could drastically improve the quality of life of users.

In the phase 2 study, CTx-1301 demonstrated a statistically significant higher concentration (<0.05) compared to Focalin XR from 9-16 hours in both low and high doses.

Recent Videos
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
Boadie Dunlop, MD, Weighs in on FDA Advisory Vote on Lykos’ MDMA
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Viability of Elamipretide for Geographic Atrophy in Dry AMD | Image Credit: HCPLive
Advancing Elamipretide into Phase 3 ReNEW and ReGAIN Trials | Image Credit: HCPLive
Elamipretide in ReCLAIM-2 Trial | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.